Diffuse Intrinsic Pontine Glioma and Chimeric Antigen Receptor T-Cell Therapy: An Emerging Frontier
- PMID: 39694135
- DOI: 10.1016/j.wneu.2024.123579
Diffuse Intrinsic Pontine Glioma and Chimeric Antigen Receptor T-Cell Therapy: An Emerging Frontier
Abstract
This study explores the integration of chimeric antigen receptor T-cell (CAR-T) therapy with convection-enhanced delivery (CED) as a novel approach for treating diffuse intrinsic pontine glioma, a highly aggressive pediatric brain tumor with limited treatment options. Preliminary clinical results indicate that CED improves CAR-T cell distribution within the tumor microenvironment, leading to promising antitumor responses. However, challenges such as catheter-related complications and potential on-target/off-tumor toxicity remain. Ongoing research is essential to optimize these strategies and address ethical considerations surrounding patient safety and equitable access to innovative therapies. The aim is to assess the safety, efficacy, and distribution of CAR T cells delivered directly to the tumor site via CED, thereby enhancing therapeutic outcomes while minimizing systemic side effects.
Keywords: CAR-T; CED; Pediatric tumor; Pontine glioma.
Copyright © 2025 The Author. Published by Elsevier Inc. All rights reserved.
Similar articles
-
CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.Int J Mol Sci. 2024 Jun 29;25(13):7174. doi: 10.3390/ijms25137174. Int J Mol Sci. 2024. PMID: 39000281 Free PMC article.
-
Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity.J Immunother Cancer. 2019 Jul 17;7(1):188. doi: 10.1186/s40425-019-0673-2. J Immunother Cancer. 2019. PMID: 31315671 Free PMC article.
-
Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.Balkan Med J. 2025 Jul 1;42(4):301-310. doi: 10.4274/balkanmedj.galenos.2025.2025-4-25. Balkan Med J. 2025. PMID: 40619794 Free PMC article. Review.
-
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.Nature. 2022 Mar;603(7903):934-941. doi: 10.1038/s41586-022-04489-4. Epub 2022 Feb 7. Nature. 2022. PMID: 35130560 Free PMC article. Clinical Trial.
-
Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations.Neuro Oncol. 2025 Feb 10;27(2):352-368. doi: 10.1093/neuonc/noae203. Neuro Oncol. 2025. PMID: 39450490 Review.
Cited by
-
CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence.Front Immunol. 2025 Jun 19;16:1596499. doi: 10.3389/fimmu.2025.1596499. eCollection 2025. Front Immunol. 2025. PMID: 40612954 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources